Magdalena Kotlicka-Antczak
Overview
Explore the profile of Magdalena Kotlicka-Antczak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wieckiewicz G, Florczyk I, Stoklosa M, Jurga M, Gorczyca P, Kotlicka-Antczak M
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337454
Background: Psychosis is defined as a series of symptoms that impair the mind and lead to a kind of loss of reference to reality. Development of psychosis is usually preceded...
2.
Grzejszczak J, Strzelecki D, Gabryelska A, Kotlicka-Antczak M
J Clin Med
. 2024 Feb;
13(3).
PMID: 38337437
Objectives: The impact of the COVID-19 pandemic on the psychological state of the under-18 population includes an increased risk of psychopathological symptoms development and exacerbation of already present psychiatric disorders....
3.
Grzejszczak J, Gabryelska A, Kotlicka-Antczak M, Strzelecki D
Brain Sci
. 2024 Jan;
14(1).
PMID: 38248239
Background: It has been shown that the course of COVID-19 infection in the under-18 population was in many cases sparsely symptomatic. In contrast, the impact of the pandemic on the...
4.
Grzejszczak J, Strzelecki D, Gabryelska A, Kotlicka-Antczak M
Children (Basel)
. 2023 Feb;
10(2).
PMID: 36832461
Suicide is one of the most common causes of death in the population of children and adolescents. Available data show the continuous growth of this phenomenon and the ineffectiveness of...
5.
Urban-Kowalczyk M, Kasjaniuk M, Smigielski J, Kotlicka-Antczak M
Neuropsychiatr Dis Treat
. 2022 Dec;
18:2807-2812.
PMID: 36471745
Purpose: Frontotemporal dementia (FTD) is still a clinical challenge with the highest rate of misdiagnosis and poor outcome. The pathogenetic relationship between depression and neurodegeneration remains unclear. This study evaluated...
6.
Grzejszczak J, Gabryelska A, Gmitrowicz A, Kotlicka-Antczak M, Strzelecki D
Int J Environ Res Public Health
. 2022 Nov;
19(21).
PMID: 36360840
The phenomenon of violence against children is a very complex one. There are many types of child abuse, and they are culturally dependent to a significant degree. Although studies show...
7.
Oliver D, Arribas M, Radua J, Salazar de Pablo G, De Micheli A, Spada G, et al.
Mol Psychiatry
. 2022 Jun;
27(9):3670-3678.
PMID: 35665763
Accurate prognostication of individuals at clinical high-risk for psychosis (CHR-P) is an essential initial step for effective primary indicated prevention. We aimed to summarise the prognostic accuracy and clinical utility...
8.
Urban-Kowalczyk M, Kotlicka-Antczak M, Strzelecki D, Rudecka E, Smigielski J
Neuropsychiatr Dis Treat
. 2021 Feb;
17:503-512.
PMID: 33623384
Objective: Some studies indicate the presence of elevated opioid levels in cases of schizophrenia and their relationship with negative symptoms. The pathogenesis of schizophrenia may be associated with an imbalance...
9.
Strzelecki D, Kotlicka-Antczak M, Kaczmarek B, Jerczynska H, Wysokinski A
Hum Psychopharmacol
. 2020 Nov;
36(3):e2770.
PMID: 33245168
Objective: Modulation of glutamatergic neurotransmission in schizophrenia by sarcosine leads to a reduction in primary negative symptoms, while its metabolic profile is safe. In order to extend research in the...
10.
Urban-Kowalczyk M, Kotlicka-Antczak M, Strzelecki D, Rudecka E, Smigielski J
Med Sci Monit
. 2020 Sep;
26:e924307.
PMID: 32892205
BACKGROUND Increased levels of endogenous opioids have been observed in patients with schizophrenia; however, the influence of these endogenous opioids on the biology of schizophrenia remains unclear. The aim of...